CONTACT  |  DONATE  |    
Accelerating the discovery of a cure for ALS.
NEWS

< Home






Prize4Life Applauds ALS Patients and Advocates for Testimony at FDA Public Hearing on ALS
Posted on: March 5, 2013

Cambridge, Mass. - March 5, 2013 -Prize4Life, a non-profit dedicated to accelerating the discovery of treatments and a cure for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease) by using powerful incentives to attract new people and drive innovation, acknowledges and appreciates those individuals who shared their testimony with the FDA at the public hearing on ALS held February 25, 2013.

The first-ever public ALS FDA hearing included presentations from many ALS organizations, scientists, clinicians, industry representatives, ALS patients, family members, and caregivers urging the FDA to fast track prospective drug treatment therapies.  Peter Frates, a Prize4Life Board Member and ALS patient, testified about the challenges patients and their loved-ones face battling the disease.  Additionally, Prize4life Scientific Advisory Board Member and ALS Association Chief Scientist Dr. Lucie Bruijn discussed the need to work collaboratively to accelerate treatments and a cure for ALS.

ALS is a devastating disease that attacks the nerve cells that control muscle movement leaving patients increasingly paralyzed. On average, an ALS patient will die within three to five years of diagnosis.  Avichai Kremer, Prize4Life's CEO and Founder, has been battling the disease since 2004.  Upon hearing the testimonies at the FDA hearing, Kremer issued this statement:

"Prize4Life is, and will continue to be, an active contributor in the fight to beat ALS. We will do this by working collaboratively with fellow ALS organizations, researchers, and patients as we identify, and partner to develop, the necessary missing resources and programs that will transform the ALS drug development landscape.   We support the efforts of those on the front-lines battling this disease and believe that actively communicating and working in conjunction with the FDA will lead to new treatments and a cure for ALS.  We will continue to use, our prize-for-breakthrough model, our SOD1 mouse colony, our PRO-ACT database, and our ALS Forum website to support and accelerate the efforts of current and future ALS researchers around the world.  We applaud those who testified at the public hearing for their help in accelerating the development of treatments for this terrible disease, and we will continue to work to support them with all the resources at our disposal."

Each day ALS researchers around the world add new pieces to the puzzle, discovering new genes and new biological insights, and with the critical help of clinicians and patients they are starting to fit the pieces together.  Better alignment and communication between these efforts and those of the FDA will increase the likelihood that more effective treatments for the disease will be developed to help the thousands of patients worldwide living with ALS.